Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo

Abstract

p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that p53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Agami R, Blandino G, Oren M and Shaul Y . (1999). Nature, 399, 809–813.

  • Cai WW, Mao JH, Chow CW, Damani S, Balmain A and Bradley A . (2002). Nat. Biotechnol., 20, 393–396.

  • Crook T, Nicholls JM, Brooks L, O'Nions J and Allday MJ . (2000). Oncogene, 19, 3439–3444.

  • Dohn M, Zhang S and Chen X . (2001). Oncogene, 20, 3193–3205.

  • Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T . (2002). Nature., 416, 560–564.

  • Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M and Wang JY . (1999). Nature, 399, 806–809.

  • Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J and Sidransky D . (2000). Proc. Natl. Acad. Sci. USA, 97, 5462–5467.

  • Jost CA, Marin MC and Kaelin Jr WG . (1997). Nature, 389, 191–194.

  • Kemp CJ, Wheldon T and Balmain A . (1994). Nat. Genet., 8, 66–69.

  • Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK and Lozano G . (2004). Cell., 119, 861–872.

  • Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F and Roop DR . (2000). Cancer Res., 60, 4016–4020.

  • Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A . (2004). Nature, 432, 775–779.

  • Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D and Kaelin Jr WG . (1998). Mol. Cell. Biol., 18, 6316–6324.

  • Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A . (1999). Nature, 398, 708–713.

  • Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T . (2004). Cell., 119, 847–860.

  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P . (2002). Hum. Mutat., 19, 607–614.

  • Park JJ, Sun D, Quade BJ, Flynn C, Sheets EE, Yang A, McKeon F and Crum CP . (2000). Am. J. Surg. Pathol., 24, 1414–1419.

  • Senoo M, Manis JP, Alt FW and McKeon F . (2004). Cancer Cell., 6, 85–89.

  • Stiewe T and Putzer BM . (2002). Cell Death Differ., 9, 237–245.

  • Stiewe T, Theseling CC and Putzer BM . (2002). J. Biol. Chem., 277, 14177–14185.

  • Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F . (1998). Mol. Cell., 2, 305–316.

  • Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C and McKeon F . (1999). Nature, 398, 714–718.

  • Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D . (2000). Nature, 404, 99–103.

  • Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R and Kufe D . (1999). Nature, 399, 814–817.

  • Zaika AI, Kovalev S, Marchenko ND and Moll UM . (1999). Cancer Res., 59, 3257–3263.

Download references

Acknowledgements

We thank Dr Allan Bradley (The Welcome Trust Sanger Institute, UK) and Dr Alea Mills (CSHL) for the p63 knockout mice, and Dr Frank McKeon (Department of Cell Biology, Harvard Medical School, USA) for the p73 knockout mice; the UCSF animal house staff for help with mice husbandry. This work was supported by grants from the NCI (U01 CA84244) and the DOE (DE-FG02-03ER63630). AB acknowledges support from the Barbara Bass Bakar Chair of Cancer Genetics.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Allan Balmain or Jian-Hua Mao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez-Losada, J., Wu, D., DelRosario, R. et al. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 24, 5521–5524 (2005). https://doi.org/10.1038/sj.onc.1208799

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208799

Keywords

This article is cited by

Search

Quick links